The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMNN | -69.43% | -97.81% | -53.37% | -100% |
| S&P | +14.78% | +87.14% | +13.33% | +1,145% |
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
After a history of failures, these three biotech stocks are running out of ideas and cash to keep their operations going.
A lot of things happened this past week. Let's check it out.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$167.03K | 11.7% |
| Market Cap | $12.93M | -15.9% |
| Market Cap / Employee | $517.35K | 0.0% |
| Employees | 25 | -24.2% |
| Net Income | -$3,429.12K | 29.2% |
| EBITDA | -$3,308.80K | 30.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.25M | -49.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $708.10K | -6.5% |
| Short Term Debt | $394.14K | -22.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -122.58% | -23.0% |
| Return On Invested Capital | -148.73% | -61.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,441.08K | -9.4% |
| Operating Free Cash Flow | -$4,441.08K | -9.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.25 | 33.96 | 7.75 | 3.81 | 103.02% |
| Price to Tangible Book Value | 21.93 | 46.79 | 337.51 | 3.81 | -84.44% |
| Enterprise Value to EBITDA | -2.27 | -3.40 | -4.53 | -3.31 | 152.09% |
| Return on Equity | -211.2% | -397.5% | -492.0% | -233.5% | 57.64% |
| Total Debt | $1.14M | $1.01M | $1.19M | $1.10M | -12.95% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
